Multiple Sclerosis Disease-Modifying Therapy: When to Start, What to Choose, When to Switch

Clinical Practice Update — DMT Selection for Relapsing and Progressive MS, the Escalation vs Early High-Efficacy Debate, Safety Monitoring, and Special Populations

This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.

MDA-MS-2026·16 min read

Clinical Focus

DMT initiation, selection by MS phenotype (RRMS, PPMS, active SPMS), high-efficacy vs escalation strategies, switching and stopping DMTs, JCV/PML risk management, and DMTs in pregnancy

Target Audience

Neurologists, MS specialists, general physicians managing MS referrals, pharmacists, MS nurses

Setting

MS clinics, neurology outpatient, infusion centres

Source Evidence

•AAN 2018 DMT Guideline (reaffirmed October 2024)
•ECTRIMS/EAN 2018 Pharmacological Treatment Guideline
•CMSC 2022 Best Practices in MS Therapies
•OPERA I/II, ORATORIO, EXPAND, ASCLEPIOS, ULTIMATE — Pivotal DMT Trials
•Observational Evidence on Early High-Efficacy vs Escalation Strategies (Swedish, Danish, Italian Registry Data)

Key Clinical Takeaways

The most important actionable points from this Practice Update on MS disease-modifying therapy.

Multiple sclerosis disease-modifying therapy selection pathway showing DMT categories and treatment strategy for relapsing and progressive MS — Overview of DMT selection in multiple sclerosis from diagnosis through treatment strategy decisions.

1Start a DMT promptly after diagnosis of relapsing MS — early treatment is associated with less long-term disability accumulation → When to Start
2The traditional escalation approach (start low, escalate if needed) is increasingly challenged by evidence favouring early high-efficacy therapy — two RCTs (DELIVER-MS, TREAT-MS) are ongoing to definitively answer this → Escalation vs Early High-Efficacy
3Anti-CD20 monoclonal antibodies (ocrelizumab, ofatumumab, ublituximab) have become the most widely used high-efficacy DMTs, with demonstrated superiority over interferons and teriflunomide → Choosing a DMT
4Ocrelizumab remains the only DMT with demonstrated efficacy in primary progressive MS (PPMS) — offer it to ambulatory patients who are likely to benefit → Progressive MS
5Natalizumab is highly effective but carries PML risk — check JCV antibody status before starting and monitor every 6 months; consider extended interval dosing in JCV-positive patients → Safety Monitoring
6Switch DMTs if there is breakthrough disease activity (clinical relapses, new MRI lesions, or disability progression) despite adequate treatment duration → When to Switch
7S1P receptor modulators (fingolimod, siponimod, ozanimod, ponesimod) require first-dose cardiac monitoring and are contraindicated with certain cardiac conditions → Safety Monitoring
8For women planning pregnancy, glatiramer acetate and interferons are the safest options; anti-CD20 therapies require adequate washout before conception → Pregnancy
9Monitor brain MRI approximately every 6 months after starting or switching DMT to establish a new baseline, then every 1–2 years for subclinical disease activity → Monitoring
10Do not stop DMTs without careful consideration — discontinuation studies show significant rebound disease activity, particularly after natalizumab and fingolimod → Stopping DMTs

When Should You Start a DMT — and How Aggressively?

The AAN 2018 guideline (reaffirmed 2024) recommends offering a DMT to people with relapsing forms of MS who have had recent relapses or MRI activity. Both AAN and ECTRIMS/EAN guidelines strongly emphasise early treatment initiation. The central unresolved question in MS therapeutics today is whether to begin with a moderate-efficacy agent and escalate if needed (the traditional approach), or to start with a high-efficacy therapy from the outset. Observational registry data increasingly favour early high-efficacy treatment, but definitive RCT evidence from DELIVER-MS and TREAT-MS is still awaited.

Prescribe a DMT for people with relapsing forms of MS who have had recent clinical relapses or MRI-detected disease activity, after a dedicated counselling visit about treatment options, risks, and benefits.

Strong Rec High Evidence AAN 2018 ECTRIMS/EAN 2018

Consider early high-efficacy therapy (anti-CD20 monoclonal antibody, natalizumab, alemtuzumab, or cladribine) as first-line treatment for patients with highly active disease: frequent relapses, incomplete recovery, high lesion burden, or poor prognostic features. Multiple observational studies show lower disability accumulation at 5–10 years with this approach compared to escalation.

Moderate Rec Moderate Evidence Registry Data 2019–2024

Consider offering a moderate-efficacy oral DMT (dimethyl fumarate, teriflunomide, or an S1P modulator) for patients with lower disease activity who prefer oral therapy and have a lower risk profile, with a plan to escalate if breakthrough activity occurs.

Moderate Rec High Evidence AAN 2018

Clinical Pearl: The AAN 2018 guideline predates the approval of ofatumumab, ublituximab, ozanimod, and ponesimod, and does not address the early high-efficacy question directly. Practice has evolved considerably since its publication. While the guideline was reaffirmed in 2024, clinicians should integrate its framework with newer evidence from registry studies and the evolving treatment landscape. The DELIVER-MS and TREAT-MS randomised trials are expected to provide definitive answers on escalation vs early high-efficacy approaches.

Which DMT Should You Choose?

DMT selection is driven by disease activity level, MS phenotype, patient comorbidities, pregnancy considerations, route preference, and risk tolerance. There are now over 20 FDA-approved DMTs. We organise them by efficacy tier rather than by mechanism, as this reflects the clinical decision-making framework most neurologists use.

MS Disease-Modifying Therapies by Efficacy Tier and Clinical Profile

Efficacy Tier	Key Agents	Approximate ARR Reduction vs Placebo	Best Suited For	Key Safety Considerations
Low Efficacy	Interferons (IFN-beta), glatiramer acetate, teriflunomide	~20–40%	Low disease activity; pregnancy planning (GA, IFN); patient preference for established safety profile	Injection site reactions (IFN, GA); flu-like symptoms (IFN); FDA Boxed Warning for anaphylaxis with GA (Jan 2025 — 82 global cases reported, can occur at any time including years after starting); teratogenic (teriflunomide — requires accelerated elimination before conception); hair thinning (teriflunomide)
Moderate Efficacy	Dimethyl fumarate/diroximel fumarate, S1P modulators (fingolimod, ozanimod, ponesimod), cladribine	~45–58%	Moderate disease activity; oral therapy preference; cladribine for patients wanting induction-style therapy with treatment-free intervals	Lymphopenia monitoring (all); first-dose cardiac monitoring (S1P modulators); GI side effects and flushing (fumarates); rare PML (fumarates with prolonged lymphopenia)
High Efficacy	Natalizumab, ocrelizumab, ofatumumab, ublituximab, alemtuzumab	>50% vs active comparator or >65% vs placebo	Highly active RRMS; early aggressive treatment strategy; natalizumab or anti-CD20 for severe breakthrough; ocrelizumab for PPMS	PML risk (natalizumab — JCV monitoring); infection risk (anti-CD20 — hypogammaglobulinaemia); autoimmune disorders (alemtuzumab); infusion reactions

Siponimod is specifically approved for active SPMS (EXPAND trial). It is the only S1P modulator with an SPMS indication.
Ofatumumab (SC, self-administered monthly) and ublituximab (IV every 6 months) provide anti-CD20 alternatives to ocrelizumab with different administration routes.
Rituximab is used off-label in many centres with comparable efficacy to ocrelizumab, at substantially lower cost.

What Can You Offer for Progressive MS?

Prescribe ocrelizumab for ambulatory patients with primary progressive MS (PPMS) who are likely to benefit. It is the only DMT with RCT evidence (ORATORIO trial) showing reduced disability progression in PPMS. Benefit was greatest in younger patients with inflammatory activity on MRI.

Strong Rec High Evidence AAN 2018 ORATORIO

Prescribe siponimod for patients with active secondary progressive MS (SPMS). The EXPAND trial demonstrated reduced confirmed disability progression. Benefit is limited to patients with ongoing inflammatory activity — it is unlikely to help those with pure non-active progression.

Strong Rec High Evidence EXPAND

Clinical Pearl: Progressive MS without inflammatory activity remains the greatest unmet need in MS therapeutics. BTK inhibitors (tolebrutinib, fenebrutinib) are under investigation for their potential to address smouldering neuroinflammation and compartmentalised CNS inflammation that drives progression independent of relapses. Tolebrutinib has received Breakthrough Therapy designation from the FDA for non-relapsing SPMS. Results from ongoing phase 3 trials may reshape progressive MS treatment.

Clinical Decision Pathway

Selecting a DMT: 4 Questions

Question 1: What is the MS phenotype?

Relapsing MS (RRMS, active SPMS, CIS) → Wide DMT selection. Proceed to Question 2.

PPMS → Ocrelizumab (ambulatory patients with inflammatory features get most benefit).

Non-active SPMS without relapses → Limited options; ongoing trials of BTK inhibitors; optimise symptom management and rehabilitation.

Question 2: How active is the disease?

Highly active (frequent relapses, high lesion burden, poor prognostic features) → High-efficacy therapy first-line (anti-CD20 mAb, natalizumab, alemtuzumab, cladribine).

Moderate activity → Moderate-efficacy oral agent (dimethyl fumarate, S1P modulator) or high-efficacy, depending on risk tolerance.

Low activity (CIS or single relapse with low lesion burden) → Lower-efficacy injectable or moderate oral, with close monitoring.

Question 3: Are there special considerations?

Pregnancy planned → Glatiramer acetate or interferon (ECTRIMS/EAN allows continuation until pregnancy confirmed in high-risk patients). Note: FDA added a Boxed Warning for anaphylaxis with GA (January 2025) — ensure patients are counselled. Anti-CD20: adequate washout needed (typically 6+ months).

JCV antibody positive → Avoid natalizumab if index >1.5 and prior immunosuppression, or use extended interval dosing with enhanced MRI monitoring.

Cardiac comorbidities → Avoid S1P modulators if significant AV block, bradycardia, or relevant cardiac history.

Question 4: Is the current DMT working?

Breakthrough activity on current DMT (clinical relapse, new/enlarging MRI lesions, disability progression) → Switch to a higher-efficacy agent.

Stable on current DMT for 5+ years, older age, no activity → Careful discussion about potential DMT discontinuation with continued MRI monitoring.

Evidence in Context

Early High-Efficacy vs Escalation: What the Data Show

Multiple large registry studies from Sweden, Denmark, Italy, and Australia consistently show that starting with a high-efficacy DMT within 2 years of disease onset is associated with lower EDSS scores at 5–10 years compared to an escalation strategy. A Danish study using propensity-score matching found that early high-efficacy treatment was associated with a 47% lower hazard of 6-month confirmed EDSS worsening (HR 0.53). An Italian study demonstrated that early intensive therapy resulted in a mean EDSS increase of +0.3 over 5 years compared to +1.2 with escalation. However, all evidence is observational and subject to selection bias. DELIVER-MS (primary outcome: brain volume loss at 3 years) and TREAT-MS (primary outcome: time to sustained disability up to 4.5 years) are the first RCTs designed to directly compare these strategies.

The Anti-CD20 Era: Ocrelizumab, Ofatumumab, and Ublituximab

Anti-CD20 B-cell-depleting therapies have become the backbone of high-efficacy MS treatment. Ocrelizumab (OPERA I/II for RMS, ORATORIO for PPMS) was the first to demonstrate superiority over interferon-beta and efficacy in PPMS. Ofatumumab (ASCLEPIOS I/II) showed superiority over teriflunomide with the advantage of self-administered subcutaneous injection. Ublituximab (ULTIMATE I/II) offers another IV anti-CD20 option with a 1-hour infusion time. Rituximab is used extensively off-label with comparable efficacy data from observational studies, at substantially lower cost. Long-term immunoglobulin monitoring is essential with all anti-CD20 agents, as sustained B-cell depletion can lead to hypogammaglobulinaemia and increased infection susceptibility over time.

Where AAN, ECTRIMS/EAN, and CMSC Agree and Differ

All three bodies agree on early DMT initiation, the importance of monitoring with MRI, the need to switch for breakthrough activity, and the role of ocrelizumab in PPMS. They differ mainly in emphasis: the AAN guideline is more cautious on pregnancy management (recommending stopping DMTs before conception), while ECTRIMS/EAN allows continuation of interferon or glatiramer acetate until pregnancy is confirmed in high-risk patients, and even during pregnancy in some highly active cases. The CMSC 2022 Best Practices document provides the most current practical guidance on newer agents not covered in the 2018 guidelines but does not carry formal guideline status. All three documents predate the approval of ofatumumab (2020), ublituximab (2022), and ponesimod (2021).

What We Still Don’t Know

Escalation vs early high-efficacy: Definitive RCT evidence is pending from DELIVER-MS and TREAT-MS. Until results are available, the decision remains individualised.

Treating non-active progressive MS: No approved DMT effectively addresses smouldering progression independent of relapses. BTK inhibitors are the most promising class under investigation.

When to stop DMTs: The optimal time to discontinue DMTs in stable, older patients is poorly defined. Stopping carries risk of rebound disease, particularly after natalizumab and fingolimod.

Long-term anti-CD20 safety: Hypogammaglobulinaemia and infection risk accumulate with prolonged B-cell depletion. The optimal monitoring strategy and thresholds for intervention are evolving.

References

1.Rae-Grant A, Day GS, Marrie RA, et al. Practice Guideline Recommendations: Disease-Modifying Therapies for Adults With Multiple Sclerosis. Neurology. 2018;90(17):777–788. doi:10.1212/WNL.0000000000005347
2.Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the Pharmacological Treatment of People With Multiple Sclerosis. Mult Scler. 2018;24(2):96–120. doi:10.1177/1352458517751049
3.Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis (OPERA I and II). N Engl J Med. 2017;376(3):221–234. doi:10.1056/NEJMoa1601277
4.Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (ORATORIO). N Engl J Med. 2017;376(3):209–220. doi:10.1056/NEJMoa1606468
5.Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus Placebo in Secondary Progressive Multiple Sclerosis (EXPAND). Lancet. 2018;391(10127):1263–1273. doi:10.1016/S0140-6736(18)30475-6
6.He A, Merkel B, Brown JWL, et al. Timing of High-Efficacy Therapy for Multiple Sclerosis: A Retrospective Observational Cohort Study. Lancet Neurol. 2020;19(4):307–316. doi:10.1016/S1474-4422(20)30067-3
7.Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis (ASCLEPIOS I and II). N Engl J Med. 2020;383(6):546–557. doi:10.1056/NEJMoa1917246

How to Read the Evidence Tags

Every recommendation carries two tags. These are Medaptly’s own simplified interpretations.

Recommendation Strength

Tag	Meaning	In Practice
Strong Rec	Benefits clearly outweigh risks.	Standard practice.
Moderate Rec	Evidence favours benefit; some uncertainty.	Most patients should receive this.
Conditional Rec	Benefit less certain; individualise.	Shared decision-making.
Against	No benefit or risks outweigh benefits.	Avoid.

Evidence Quality

Tag	Meaning	Confidence
High Evidence	Multiple RCTs or meta-analyses.	Very confident.
Moderate Evidence	Single RCT or large observational studies.	Reasonably confident.
Low Evidence	Expert consensus or small studies.	Less certain.

These are Medaptly’s simplified interpretations. For full classification systems, consult the original documents in References.

Article Information

For Educational Purposes Only. This is original clinical education content informed by current published guidelines and clinical evidence. It does not constitute medical advice, is not endorsed by any guideline body (AAN, ECTRIMS, EAN, CMSC, or any other organisation), and does not replace individualised clinical judgement, institutional protocols, or local formulary guidance. Drug dosages should always be verified against current prescribing information. Readers are encouraged to consult the original source guidelines listed in the References section for the full evidence review and complete recommendation sets.